Cargando…
Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
Soluble B and T lymphocyte attenuator (sBTLA) has been shown to be associated with severity and outcome, in critically ill septic patients. We aimed to assess the dynamic expression of sBTLA, as a prognostic biomarker of long-term mortality in patients with bloodstream infection (BSI) and sepsis, an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936450/ https://www.ncbi.nlm.nih.gov/pubmed/35312715 http://dx.doi.org/10.1371/journal.pone.0265818 |
_version_ | 1784672221141139456 |
---|---|
author | Lange, Anna Cajander, Sara Magnuson, Anders Strålin, Kristoffer Hultgren, Olof |
author_facet | Lange, Anna Cajander, Sara Magnuson, Anders Strålin, Kristoffer Hultgren, Olof |
author_sort | Lange, Anna |
collection | PubMed |
description | Soluble B and T lymphocyte attenuator (sBTLA) has been shown to be associated with severity and outcome, in critically ill septic patients. We aimed to assess the dynamic expression of sBTLA, as a prognostic biomarker of long-term mortality in patients with bloodstream infection (BSI) and sepsis, and to evaluate its association with biomarkers indicative of inflammation and immune dysregulation. Secondarily, sBTLA was evaluated in association with severity and bacterial etiology. Patients with BSI (n = 108) were prospectively included, and serially sampled from admission to day 28. Blood and plasma donors (n = 31), sampled twice 28 days apart, served as controls. sBTLA concentration in plasma was determined with enzyme-linked immunosorbent assay. Associations between sBTLA on day 1–2 and 7, and mortality at 90 days and 1 year, were determined with unadjusted, and adjusted Cox regression. Differences related to severity was assessed with linear regression. Mixed model was used to assess sBTLA dynamics over time, and sBTLA associations with bacterial etiology and other biomarkers. sBTLA on day 1–2 and 7 was associated with mortality, in particular failure to normalize sBTLA by day 7 was associated with an increased risk of death before day 90, adjusted HR 17 (95% CI 1.8–160), and one year, adjusted HR 15 (95% CI 2.8–76). sBTLA was positively associated with CRP, and negatively with lymphocyte count. sBTLA on day 1–2 was not linearly associated with baseline SOFA score increase. High SOFA (≥4) was however associated with higher mean sBTLA than SOFA ≤3. sBTLA was not associated with bacterial etiology. We show that sustained elevation of sBTLA one week after hospital admission is associated with late mortality in patients with BSI and sepsis, and that sBTLA concentration is associated with CRP and decreased lymphocyte count. This suggests that sBTLA might be an indicator of sustained immune-dysregulation, and a prognostic tool in sepsis. |
format | Online Article Text |
id | pubmed-8936450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-89364502022-03-22 Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis Lange, Anna Cajander, Sara Magnuson, Anders Strålin, Kristoffer Hultgren, Olof PLoS One Research Article Soluble B and T lymphocyte attenuator (sBTLA) has been shown to be associated with severity and outcome, in critically ill septic patients. We aimed to assess the dynamic expression of sBTLA, as a prognostic biomarker of long-term mortality in patients with bloodstream infection (BSI) and sepsis, and to evaluate its association with biomarkers indicative of inflammation and immune dysregulation. Secondarily, sBTLA was evaluated in association with severity and bacterial etiology. Patients with BSI (n = 108) were prospectively included, and serially sampled from admission to day 28. Blood and plasma donors (n = 31), sampled twice 28 days apart, served as controls. sBTLA concentration in plasma was determined with enzyme-linked immunosorbent assay. Associations between sBTLA on day 1–2 and 7, and mortality at 90 days and 1 year, were determined with unadjusted, and adjusted Cox regression. Differences related to severity was assessed with linear regression. Mixed model was used to assess sBTLA dynamics over time, and sBTLA associations with bacterial etiology and other biomarkers. sBTLA on day 1–2 and 7 was associated with mortality, in particular failure to normalize sBTLA by day 7 was associated with an increased risk of death before day 90, adjusted HR 17 (95% CI 1.8–160), and one year, adjusted HR 15 (95% CI 2.8–76). sBTLA was positively associated with CRP, and negatively with lymphocyte count. sBTLA on day 1–2 was not linearly associated with baseline SOFA score increase. High SOFA (≥4) was however associated with higher mean sBTLA than SOFA ≤3. sBTLA was not associated with bacterial etiology. We show that sustained elevation of sBTLA one week after hospital admission is associated with late mortality in patients with BSI and sepsis, and that sBTLA concentration is associated with CRP and decreased lymphocyte count. This suggests that sBTLA might be an indicator of sustained immune-dysregulation, and a prognostic tool in sepsis. Public Library of Science 2022-03-21 /pmc/articles/PMC8936450/ /pubmed/35312715 http://dx.doi.org/10.1371/journal.pone.0265818 Text en © 2022 Lange et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Lange, Anna Cajander, Sara Magnuson, Anders Strålin, Kristoffer Hultgren, Olof Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
title | Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
title_full | Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
title_fullStr | Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
title_full_unstemmed | Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
title_short | Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
title_sort | sustained elevation of soluble b- and t- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936450/ https://www.ncbi.nlm.nih.gov/pubmed/35312715 http://dx.doi.org/10.1371/journal.pone.0265818 |
work_keys_str_mv | AT langeanna sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis AT cajandersara sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis AT magnusonanders sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis AT stralinkristoffer sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis AT hultgrenolof sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis |